Charles Schwab Investment Management Inc. Has $608,000 Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC)

Charles Schwab Investment Management Inc. lessened its stake in Century Therapeutics, Inc. (NASDAQ:IPSC) by 10.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 355,331 shares of the company’s stock after selling 43,049 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Century Therapeutics were worth $608,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in IPSC. SG Americas Securities LLC bought a new stake in shares of Century Therapeutics in the third quarter valued at about $27,000. Rhumbline Advisers grew its stake in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after acquiring an additional 18,828 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Century Therapeutics by 141.7% in the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after purchasing an additional 44,155 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Century Therapeutics by 110.1% in the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock worth $380,000 after purchasing an additional 78,088 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Century Therapeutics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after purchasing an additional 9,500 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Wall Street Analysts Forecast Growth

IPSC has been the topic of several analyst reports. Chardan Capital cut their price target on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reduced their price target on Century Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $11.60.

Century Therapeutics Price Performance

Century Therapeutics stock opened at $1.05 on Thursday. Century Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $5.51. The firm has a market capitalization of $88.86 million, a PE ratio of -0.56 and a beta of 1.65. The company’s 50-day moving average is $1.40 and its 200-day moving average is $1.88.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The firm had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. During the same quarter in the prior year, the company earned ($0.55) earnings per share. As a group, analysts expect that Century Therapeutics, Inc. will post -1.63 EPS for the current year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.